吸入布地奈德治疗高海拔地区慢性肺心病急性加重期患者的临床疗效及作用机制  

Therapeutic effects of inhalation of budesonide on the patients with acute exacerbations of chronic cor pulmonale and its mechanisms at high altitude

作　　者：杨生岳[1] 冯恩志[1] 沈君礼[1] 郭振援[1] 黄宁侠[1] 张瑛[1] 陈宗茹[1] 张华[1] 

机构地区：[1]解放军第四医院呼吸内科,青海西宁810007

出　　处：《西北国防医学杂志》2009年第6期404-406,共3页Medical Journal of National Defending Forces in Northwest China

基　　金：青海省重点科技攻关项目(2006-N-143)

摘　　要：目的:观察吸入布地奈德治疗高海拔地区慢性肺心病急性加重期的临床疗效。方法:高海拔地区慢性肺心病急性加重期患者86例,随机分为3组。3组常规治疗相同,对照组雾化吸入沙丁胺醇2 mg,治疗1组和2组分别联用雾化吸入布地奈德2 mg和3 mg,均为1次/8 h。治疗前、后进行临床评分、测痰中IL-8、TNF-α、PaO2、PaCO2。结果:治疗后第3、7、10天,治疗1、2组痰中IL-8、TNF-α、PaCO2、临床评分显著低于对照组(P<0.01或P<0.05),PaO2显著高于对照组(P<0.05),治疗2组优于1组(P<0.01或P<0.05)。结论:布地奈德联合沙丁胺醇雾化吸人治疗高海拔地区慢性肺心病急性加重期可取得更好效果。Objective：To investigate the therapeutic effect of inhalation of budesonide（BUD） suspension on the patients with acute exacerbations of chronic cor pulmonale（HACCP） at high altitude.Methods：86 patients with acute exacerbations of HACCP were divided into three groups.The control group received 2 mg salbutamol every 8 h.The other two groups received 2 mg（group I） or 3 mg（groupII） BUD and 2 mg salbutamol every 8 h.The concentration of IL-8 and TNF-α in sputum,PaO2 and PaCO2,and clinical scores were examined before and after treatment.Results：After 3,7,10 days of treatment,the concentration of IL-8 and TNF-α in sputum,PaCO2 and clinical scores in group I and group II were significantly lower,while PaO2was significantly higher than those of the control group（P〈0.01 or P〈0.05）.This tendency was more obvious in group I than in group II（P〈0.01 or P〈0.05）.Conclusion：The combination of inhalation of BUD with salbutamol can obtain better therapeutic effect for the patients with acute exacerbations of HACCP.

关 键 词：肺疾病 阻塞性 肺心病 布地奈德 药物疗法 高海拔 

分 类 号：R541.5[医药卫生—心血管疾病]